dc.contributor.author | Guzman-Fulgencio, Maria | |
dc.contributor.author | Berenguer, Juan | |
dc.contributor.author | Rallón, Norma | |
dc.contributor.author | Fernandez-Rodriguez, Amanda | |
dc.contributor.author | Miralles, Pilar | |
dc.contributor.author | Soriano, Vicente | |
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.contributor.author | Cosín, Jaime | |
dc.contributor.author | Medrano, José | |
dc.contributor.author | Garcia-Alvarez, Monica | |
dc.contributor.author | López, Juan C | |
dc.contributor.author | Benito, José M | |
dc.contributor.author | Resino, Salvador | |
dc.date.accessioned | 2024-02-04T19:06:38Z | |
dc.date.available | 2024-02-04T19:06:38Z | |
dc.date.issued | 2013-05-15 | |
dc.identifier.citation | AIDS. 2013 May 15;27(8):1231-8. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/17448 | |
dc.description.abstract | Objectives: To analyze whether human leukocyte antigen (HLA)-E allelic variants are associated with and may predict response to peg-interferon (IFN) alpha and ribavirin treatment in HIV/hepatitis C virus (HCV)-coinfected patients. Design: Retrospective follow-up study. Methods: We studied 321 naive patients who started HCV treatment. HLA-E genotyping was performed by restriction fragment length polymorphism. A sustained virological response (SVR) was defined as undetectable plasma HCV-RNA up through 24 weeks after the end of HCV treatment. Results: The HLA-E*0101 allele increased the odds of achieving SVR for all patients [adjusted odds ratio (aOR) = 2.03 (95% confidence interval, 95% CI = 1.35-3.06); P = 0.001], for HCV genotype (GT) 1/4 patients (aOR = 1.62 (95% CI = 1.03-2.54), P = 0.035), and for GT2/3 patients [aOR = 9.87 (95% CI = 2.47-31.89), P = 0.001]. For decision tree analysis, the SVR rate increased from 0 to 82.6% and then to 92.5% in GT2/3 patients when the count of HLA-E*0101 alleles increased. In GT1/4 patients with rs8099917 TT genotype, the SVR rate increased from 33.3 to 54.8% and then to 61.8% when the count of HLA-E*0101 alleles increased. In GT1/4 patients with rs8099917 GT/GG genotype, the SVR rate increased from 15.4 to 22% and then to 44% when the count of HLA-E*0101 alleles increased. The overall percentage of patients correctly classified was 73.2% and the area under the receiver operating characteristic curve (AUROC) was 0.803 ± 0.024. Conclusion: The HLA-E*0101 allele was associated with increased odds of HCV clearance and could help to predict SVR among HIV/HCV-coinfected patients on HCV therapy. This would be helpful to avoid treatment in those less likely to respond to pegylated-interferon-alpha and ribavirin treatment. | es_ES |
dc.description.sponsorship | This work has been supported by grants given by Instituto de Salud Carlos III (Ref. PI08/0738, ISCIII-RETIC RD12/0017 and PI11/00245 to S.R.; Ref. ISCIII-RETIC RD06/006, PI08/0928, and PI11/01556 to J.B.; and Ref. PI11/00870 to J.M.B.), Fundación para la Investigación y la Prevención del Sida en España (FIPSE) (Ref. 361020/10 to J.B.) and Fundación para la Investigación y la Educación en SIDA (F-IES). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Lippincott Williams & Wilkins (LWW) | es_ES |
dc.type.hasVersion | AM | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | AIDS | es_ES |
dc.subject | Hepatitis C virus clearance | es_ES |
dc.subject | Hepatitis C virus therapy | es_ES |
dc.subject | HLA-E | es_ES |
dc.subject | IL28B | es_ES |
dc.subject | Single nucleotide polymorphism | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Alleles | es_ES |
dc.subject.mesh | Antiviral Agents | es_ES |
dc.subject.mesh | Coinfection | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Follow-Up Studies | es_ES |
dc.subject.mesh | Genotyping Techniques | es_ES |
dc.subject.mesh | HIV Infections | es_ES |
dc.subject.mesh | Hepatitis C, Chronic | es_ES |
dc.subject.mesh | Histocompatibility Antigens Class I | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Interferon alpha-2 | es_ES |
dc.subject.mesh | Interferon-alpha | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Polyethylene Glycols | es_ES |
dc.subject.mesh | Polymorphism, Single Nucleotide | es_ES |
dc.subject.mesh | Recombinant Proteins | es_ES |
dc.subject.mesh | Retrospective Studies | es_ES |
dc.subject.mesh | Ribavirin | es_ES |
dc.subject.mesh | Viral Load | es_ES |
dc.subject.mesh | HLA-E Antigens | es_ES |
dc.title | HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 23811951 | es_ES |
dc.format.volume | 27 | es_ES |
dc.format.number | 8 | es_ES |
dc.format.page | 1231-1238 | es_ES |
dc.identifier.doi | 10.1097/QAD.0b013e32835f5b9c | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Fundación para la Investigación y la Prevención del Sida en España | es_ES |
dc.contributor.funder | Fundación para la Investigación y la Educación en SIDA (F-IES) | es_ES |
dc.contributor.funder | RETICS-Sida (RIS-ISCIII) (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1473-5571 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1097/QAD.0b013e32835f5b9c | es_ES |
dc.identifier.journal | AIDS (London, England) | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0012/ES/SIDA/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//PI11%2F00245/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//PI11%2F01556/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//PI11%2F00870/ES/Caracterización Inmunológica y Molecular del Aclaramiento Viral en Respuesta al Tratamiento en Pacientes con Infección Crónica por el Virus de la Hepatitis C y coinfectados con VIH/ | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI08/0738 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/RD06/006 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI08/0928 | es_ES |